Glenmark receives USFDA approval for Clotrimazole, Betamethasone Dipropionate Cream

09 Nov 2015 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Clotrimazole and Betamethasone Dipropionate Cream USP, 1% 0.05%, the therapeutic equivalent of Lotrisone Cream USP, 1% 0.05% of Merck, Sharp and Dohme Corporation.

According to IMS Health sales data for the 12 month period ending September 2015, the Lotrisone Cream USP, 1% 0.05% market1 achieved annual sales of approximately $82.4 million.

Glenmark’s current portfolio consists of 103 products authorized for distribution in the US marketplace and 63 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

2025.40 -10.50 (-0.52%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×